Merck Tbk PT

Merck Tbk PT PEG

The PEG Ratio (Price/Earnings-to-Growth) of Merck Tbk PT (MERK.JK) as of Oct 16, 2026 is 0.55. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.87 — a change of -37.08% (lower).

PEG

0.55

YoY

-37.08%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Merck Tbk PT is 2025 0.55 . PEG Ratio (Price/Earnings-to-Growth) of Merck Tbk PT was 2024 0.87 . It decreases by -37.08% lower compared to the previous year.

The Merck Tbk PT PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2018
0.12 IDR
Jan 1, 2019
1.71 IDR
Jan 1, 2020
1.87 IDR
Jan 1, 2021
1.02 IDR
Jan 1, 2022
0.75 IDR
Jan 1, 2023
0.75 IDR
Jan 1, 2024
0.87 IDR
Jan 1, 2025
0.55 IDR
The Merck Tbk PT PEG history
YEARPEGYoY
0.55-37.08%
0.87+16.14%
0.75+0.90%
0.75-26.79%
1.02-45.39%
1.87+8.84%
1.71+1,386.55%
0.12-87.56%
0.93+6.34%
0.87-7.34%
0.94+27.31%
0.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Merck Tbk PT Stock analysis

What does Merck Tbk PT do? Merck Tbk PT is a pharmaceutical company based in Jakarta Timur, DKI Jakarta, operating within the Health Care sector. The company, listed on the Indonesian stock exchange with ticker MERK.JK and ISIN ID1000136609, has been publicly traded since its IPO on July 23, 1981. It employs 376 full-time staff and focuses on the development and distribution of pharmaceutical and chemical products. The company operates through three business segments: Biopharma, which covers ethical pharmaceutical products; Consumer Health, which includes over-the-counter products; and Others, which encompasses additional business activities. Merck Tbk PT is committed to providing personalized treatments for serious diseases and supports initiatives related to reproductive health, including enabling individuals to achieve their goal of becoming parents. The company's official website is https://www.merckgroup.com/id-id, where further information about its operations and services can be accessed. As a publicly listed entity, Merck Tbk PT is subject to regulatory disclosures and financial reporting requirements in Indonesia. The company's primary focus remains on delivering healthcare solutions through its pharmaceutical and chemical offerings, targeting both professional medical markets and consumer health needs. Merck Tbk PT is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merck Tbk PT stock

PEG Ratio (Price/Earnings-to-Growth) of Merck Tbk PT is 0.55 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Merck Tbk PT changed from 0.87 to 0.55, representing a -37.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Merck Tbk PT since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Merck Tbk PT with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Merck Tbk PT

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Merck Tbk PT